Xintela and NorthX Biologics announce they have signed a collaboration framework agreement to facilitate projects of common interest utilizing their complementary resources and competences in developing and manufacturing Advanced Therapy Medicinal Products (ATMPs). Projects to be initiated under the collaboration framework include product and process development, quality management and expansion capacity for manufacturing ATMPs, among other things.
“This is a very exciting opportunity for us. Xintela has developed the superior stem cell product XSTEM, which is now in clinical development, and has strong competence in process development and GMP manufacturing of stem cells and other ATMPs. Together with NorthX Biologics and their manufacturing capacity we can further expand and also broaden our ATMP business”, says Evy Lundgren-Åkerlund, CEO of Xintela.
“This collaboration is another step in the right direction towards becoming a leading solutions provider in the cell and gene therapy space, adding to the solid competence NorthX already gained from +30 years of advanced biological GMP manufacturing. I am excited to work with Xintela and look forward to our relationship going forward”, says Helena Strigård, CEO of NorthX Biologics.